Company Encyclopedia
View More
name
HEPALINK
09989.HK
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. provides pharmaceutical products in Hong Kong, the United States, Europe, Mainland China, and internationally. It operates in four segments: Finished Dose Pharmaceutical Products, Active Pharmaceutical Ingredients (API), Contract Development and Manufacturing Organization (CDMO), and Others. The company offers finished dose pharmaceutical products, such as prolongin, inhixa, neoparin, and heparin and enoxaparin sodium injections; API products, including heparin and enoxaparin sodium APIs; and pancreatin API.
1.450 T
09989.HKMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
PharmaceuticalsIndustry
Industry Ranking24/48
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreC
    • ROE3.43%C
    • Profit Margin7.80%B
    • Gross Margin35.79%C
  • Growth ScoreC
    • Revenue YoY-1.97%D
    • Net Profit YoY384.25%A
    • Total Assets YoY-6.79%D
    • Net Assets YoY0.32%C
  • Cash ScoreC
    • Cash Flow Margin1281.39%B
    • OCF YoY-1.97%D
  • Operating ScoreD
    • Turnover0.31D
  • Debt ScoreB
    • Gearing Ratio27.46%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Shenzhen Hepalink Pharmaceutical Group Co. Ltd. Announces Date for First Extraordinary General Meeting

    Shenzhen Hepalink Pharmaceutical Group Co. Ltd. will hold its first extraordinary general meeting of 2025 on December 16 at L’Hermitage Hotel in Shenzhen. Shareholders will vote on key proposals, including the abolition of the Supervisory Committee, amendments to the Articles of Association, internal governance measures, and the election of an independent non-executive director.

    Reuters·
    HK
    09989
    -0.56%
    SZ
    002399
    -0.25%
    Reuters·
    HK
    09989
    -0.56%
    SZ
    002399
    -0.25%

    Shenzhen Hepalink Releases 2025 Q3 Financial Report

    Shenzhen Hepalink Pharmaceutical Group Co., Ltd. has released its unaudited Q3 financial report for 2025, covering the nine months ending September 30. The report, approved by the board, emphasizes transparency and regulatory compliance, which may enhance investor confidence. The latest analyst rating for its stock (HK:9989) is a Sell, with a price target of HK$4.31. The company operates in the pharmaceutical sector and is listed on the Hong Kong Stock Exchange, with a current market cap of HK$17.59B.

    Tip Ranks·
    HK
    09989
    -0.56%
    SZ
    002399
    -0.25%
    Tip Ranks·
    HK
    09989
    -0.56%
    SZ
    002399
    -0.25%

    HEPALINK released its performance for the first three quarters, with a net profit attributable to the parent company of 554 million yuan, a year-on-year decrease of 29.04%

    According to the Zhitong Finance APP, Hepalink released its third-quarter report for 2025. As of September 30, 2025, the company achieved operating revenue of RMB 4.194 billion, an increase of 3.09% year-on-year; the net profit attributable to shareholders of the listed company was RMB 554 million, a decrease of 29.04% year-on-year; the basic earnings per share were RMB 0.3773

    Zhitong·
    SZ
    002399
    -0.25%
    HK
    09989
    -0.56%
    Zhitong·
    SZ
    002399
    -0.25%
    HK
    09989
    -0.56%

    Shenzhen Hepalink Schedules Board Meeting to Review Q3 Results

    Shenzhen Hepalink Pharmaceutical Group Co., Ltd. has scheduled a board meeting for October 30, 2025, to review its Q3 results for the period ending September 30, 2025. This meeting is crucial for understanding the company's financial performance and strategic direction. The latest analyst rating for its stock (HK:9989) is a Sell, with a price target of HK$4.31. The company operates in the pharmaceutical sector, focusing on heparin products and related services, with a current market cap of HK$17.23B.

    Tip Ranks·
    SZ
    002399
    -0.25%
    HK
    09989
    -0.56%
    Tip Ranks·
    SZ
    002399
    -0.25%
    HK
    09989
    -0.56%

    HEPALINK released its performance for the first half of the year, with a net profit attributable to the parent company of 422 million yuan, a year-on-year decrease of 36.44%

    According to the Zhitong Finance APP, Hepalink released its semi-annual report for 2025. During the reporting period, the company achieved operating revenue of 2.817 billion yuan, a year-on-year decrease of 0.71%. The net profit attributable to shareholders of the listed company was 422 million yuan, a year-on-year decrease of 36.44%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 426 million yuan, a year-on-year increase of 29.34%. The basic earnings per share were 0.2875 yuan

    Zhitong·
    SZ
    002399
    -0.25%
    HK
    09989
    -0.56%
    Zhitong·
    SZ
    002399
    -0.25%
    HK
    09989
    -0.56%
    © 2025 Longbridge｜Disclaimer